Cargando…

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?

BACKGROUND: In January 2019, the Clinical and Laboratory Standards Institute (CLSI) lowered breakpoints of fluoroquinolones (FQ) for Enterobacteriaceae (EB)and Pseudomonas aeruginosa (PsAr). Automated commercial antimicrobial susceptibility testing (cAST) can only report levofloxacin MIC ≤1 μg/mL ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sansom, Sarah, Moore, Nicholas M, Kazi, Aamir S, Won, Sarah Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810838/ http://dx.doi.org/10.1093/ofid/ofz360.1864

Ejemplares similares

Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision
por: Wang, Ying, et al.
Publicado: (2021)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

1549. Impact of New Fluoroquinolone Breakpoints on Enterobacteriaceae Susceptibility Rates and Clinical Outcomes
por: Pettit, Natasha N, et al.
Publicado: (2019)

Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use
por: MacDougall, Conan, et al.
Publicado: (2005)

Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa
por: Zhao, Lei, et al.
Publicado: (2020)

2144. Performance of 2019 CLSI Ciprofloxacin Breakpoint Antimicrobial Susceptibility Testing Algorithms for Enterobacteriaceae and Pseudomonas aeruginosa Directly from Positive Blood Culture on the Accelerate Pheno™ System
por: Shamsheyeva, Alena, et al.
Publicado: (2019)

Plasmid-Mediated Fluoroquinolone Resistance in Pseudomonas aeruginosa and Acinetobacter baumannii
por: Venkataramana, Geetha P., et al.
Publicado: (2022)

Potential Synergistic Antibiotic Combinations against Fluoroquinolone-Resistant Pseudomonas aeruginosa
por: Kothari, Ashish, et al.
Publicado: (2022)

Correlation Between Virulence Genotype and Fluoroquinolone Resistance in Carbapenem-Resistant Pseudomonas aeruginosa
por: Cho, Hye Hyun, et al.
Publicado: (2014)

Detection of Overexpression of Efflux Pump Expression in Fluoroquinolone-Resistant Pseudomonas aeruginosa Isolates
por: Al Rashed, Nouf, et al.
Publicado: (2020)

Association between Consumption of Fluoroquinolones and Carbapenems and Their Resistance Rates in Pseudomonas aeruginosa in Argentina
por: Boni, Silvia, et al.
Publicado: (2022)

Mortality Impact of CLSI Carbapenem Breakpoint Changes in Enterobacteriaceae Bloodstream Infections: a Patient-level Analysis of Published Data
por: O’Donnell, J Nicholas, et al.
Publicado: (2017)

1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States
por: Flamm, Robert K, et al.
Publicado: (2019)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas aeruginosa
por: Kosai, Kosuke, et al.
Publicado: (2018)

Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas Aeruginosa
por: Kosai, Kosuke, et al.
Publicado: (2017)

Intra-ocular Predation of Fluoroquinolone-Resistant Pseudomonas aeruginosa and Serratia marcescens by Predatory Bacteria
por: Romanowski, Eric G., et al.
Publicado: (2023)

647. Adoption of the updated fluoroquinolones breakpoints for Gram negative bacteria in clinical microbiology laboratories
por: Sfeir, Maroun M
Publicado: (2020)

Characterization of fluoroquinolone resistance and qnr diversity in Enterobacteriaceae from municipal biosolids
por: Kaplan, Ella, et al.
Publicado: (2013)

667. Multicenter Assessment of Enterobacterales, Salmonella spp. and Pseudomonas aeruginosa Using Updated CLSI Levofloxacin Breakpoints on MicroScan Dried Gram Negative MIC Panels
por: Garner, Omai, et al.
Publicado: (2020)

Impact of Reappraisal of Fluoroquinolone Minimum Inhibitory Concentration Susceptibility Breakpoints in Gram-Negative Bloodstream Isolates
por: Shealy, Stephanie C., et al.
Publicado: (2020)

Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
por: Lee, Ching-Chi, et al.
Publicado: (2019)

Genomic and phenotypic characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Durban, South Africa
por: Osei Sekyere, John, et al.
Publicado: (2017)

Evaluation of automated systems for aminoglycosides and fluoroquinolones susceptibility testing for Carbapenem-resistant Enterobacteriaceae
por: Zhao, Zhichang, et al.
Publicado: (2017)

Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints
por: Kuti, Joseph L, et al.
Publicado: (2018)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023)

Prevalence of resistance to aminoglycosides and fluoroquinolones among Pseudomonas aeruginosa strains in a University Hospital in Northeastern Poland
por: Michalska, Anna Diana, et al.
Publicado: (2015)

Fitness Cost of Fluoroquinolone Resistance in Clinical Isolates of Pseudomonas aeruginosa Differs by Type III Secretion Genotype
por: Agnello, Melissa, et al.
Publicado: (2016)

The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran
por: Nouri, Roghayeh, et al.
Publicado: (2016)

Targeting Bacterial Gyrase with Cystobactamid, Fluoroquinolone, and Aminocoumarin Antibiotics Induces Distinct Molecular Signatures in Pseudomonas aeruginosa
por: Franke, Raimo, et al.
Publicado: (2021)

Beta-Lactam vs. Fluoroquinolone Monotherapy for Pseudomonas aeruginosa Infection: A Systematic Review and Meta-Analysis
por: Reid, Eric, et al.
Publicado: (2021)

Fluoroquinolone Versus Nonfluoroquinolone Treatment of Bloodstream Infections Caused by Chromosomally Mediated AmpC-Producing Enterobacteriaceae
por: Gunter, Sarah Grace, et al.
Publicado: (2020)

Etymologia: Fluoroquinolone
por: Henry, Ronne
Publicado: (2017)

Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance
por: Lim, Sue, et al.
Publicado: (2003)

673. Updated CLSI Ciprofloxacin Breakpoints from a Multicenter Assessment for Enterobacterales, Salmonella spp. and Pseudomonas aeruginosa Using MicroScan Dried Gram Negative MIC Panels
por: Traczewski, Maria M, et al.
Publicado: (2020)

786. Facility Reported vs. CLSI MIC Breakpoint Comparison of Carbapenem Non-susceptible (Carb-NS) Pseudomonas aeruginosa (PSA) From 2016-2019: A Multicenter Evaluation
por: Gupta, Vikas, et al.
Publicado: (2021)

Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions
por: Shen, Gwan-Han, et al.
Publicado: (2012)

Trends in Fluoroquinolone (Ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990–1999
por: Livermore, David M., et al.
Publicado: (2002)

1072. Streamlining to Oral β-Lactam vs. Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
por: Fong, Karen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_76h839jj7queo75k81ko8sm8g6